🏅 FDA Orphan Designation

Istodax

romidepsin

Manufacturer: Celgene Corporation

Indicated for:

T-cell non-Hodgkin lymphomaOrphanPrimary cutaneous T-cell lymphoma

FDA-Approved Indications (2)

T-cell non-Hodgkin lymphomaOrphan Designation

Treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy

Primary cutaneous T-cell lymphoma

ISTODAX is indicated for the treatment of cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy

Population: adults

Indications & Usage

1 INDICATIONS AND USAGE ISTODAX is indicated for the treatment of cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy. ISTODAX is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy ( 1 ).

💙 Support Programs

View all →

ISTODAX

Bristol Myers Squibb

Copay card ↗Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.